ArticleAmerican journal of translational research2025
The effect of sacubitril/valsartan sodium on cardiac function and ventricular remodeling in patients with heart failure after PCI for acute myocardial infarction.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the effect of sacubitril/valsartan sodium on patients with heart failure following percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI), with a focus on changes in cardiac function and vascular endothelial function.
methodsThis retrospective study analyzed data from 108 patients diagnosed with AMI and heart failure after PCI between June 2023 and June 2024. Patients were allocated into two groups based on the treatment regimen. The control group received standard therapy supplemented with valsartan. The study group received sacubitril/valsartan sodium in place of valsartan, in addition to the same standard regimen. Key outcome measures included markers of myocardial injury [cardiac troponin I (cTnI), high-sensitivity C-reactive protein (hs-CRP), and N-terminal pro-brain natriuretic peptide (NT-proBNP)], echocardiographic parameters, indices of cardiac function and ventricular remodeling, six-minute walk distance (6MWD), Kansas City Cardiomyopathy Questionnaire (KCCQ) scores, major adverse cardiovascular events (MACEs), and incidence of adverse reactions.
resultsBaseline characteristics were comparable between the two groups. Post-treatment, the study group demonstrated a significantly higher clinical efficacy (P < 0.05). Myocardial injury markers decreased more markedly, and improvements in cardiac function were significantly greater in the study group compared to the control group (P < 0.05). Although the study group exhibited lower incidences of MACEs and adverse reactions, the differences were not statistically significant.
conclusionSacubitril/valsartan sodium can significantly improve cardiac function and vascular endothelial function and attenuate ventricular remodeling in patients with heart failure after PCI for AMI. The treatment is well tolerated and demonstrates a favorable safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.